Salarius Pharmaceuticals (SLRX)
(Delayed Data from NSDQ)
$1.77 USD
+0.06 (3.51%)
Updated Sep 18, 2024 03:59 PM ET
After-Market: $1.86 +0.09 (5.08%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.77 USD
+0.06 (3.51%)
Updated Sep 18, 2024 03:59 PM ET
After-Market: $1.86 +0.09 (5.08%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Salarius (SLRX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Salarius (SLRX) delivered earnings and revenue surprises of 11.11% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Salarius (SLRX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Salarius (SLRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sage Therapeutics (SAGE) in Focus: Stock Moves 9.3% Higher
by Zacks Equity Research
Sage Therapeutics (SAGE) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.